2026-07-01
Does Nicotinamide Really Prevent Skin Cancer?
Dermatology and Venereology
By Ana Espino | Published on July 01, 2026 | 4 min read
Nicotinamide, a form of vitamin B3, has attracted growing interest in recent years as a potential strategy for preventing non-melanoma skin cancers. Inexpensive, well tolerated, and readily available, it is already recommended by some dermatologists for patients at high risk of developing new skin cancers. However, despite encouraging findings from several studies, its true clinical effectiveness remains a matter of debate.
In a critical review published in the American Journal of Clinical Dermatology, Eugene Tan and Hywel Williams reassess the latest scientific evidence on nicotinamide. The authors examine, in particular, a large retrospective study involving more than 33,000 U.S. veterans, along with the major meta-analyses published in recent years, to determine whether current evidence is sufficient to support its routine use in clinical practice.
Read next : Skin Cancer: Is Sunscreen Still Enough to Protect Us?
The most recent retrospective study reported a 14% reduction in the overall risk of skin cancer among patients receiving nicotinamide, with a 22% reduction in the risk of cutaneous squamous cell carcinoma. The benefits appeared to be greater when treatment was initiated early, following a patient's first episode of skin cancer.
However, the authors caution that these findings should be interpreted carefully. The study has several important methodological limitations that may have overestimated the observed protective effect. These include the absence of information on major risk factors such as skin phototype, cumulative ultraviolet exposure, and photoprotection habits, as well as the potential for selection bias, difficulties in verifying long-term treatment adherence, and a study population composed almost exclusively of older men, limiting the generalizability of the results.
Researchers also place these new findings within the broader context of previous clinical trials and meta-analyses. While the ONTRAC trial, published in 2015, demonstrated a protective effect of nicotinamide in high-risk patients, other studies—particularly those involving solid organ transplant recipients—failed to show a significant benefit. Likewise, the two most recent systematic reviews concluded that the available evidence remains low in quality and does not allow a definitive conclusion that nicotinamide reduces the incidence of skin cancer.
Read next : What If Nanotechnology Redefined the Future of Sunscreens?
This review highlights that nicotinamide has a biologically plausible mechanism of action, notably by promoting the repair of UV-induced DNA damage and improving the energy metabolism of skin cells. Nevertheless, the authors argue that biological plausibility alone is not sufficient to justify routine clinical recommendations in the absence of robust clinical evidence.
They emphasize that current data rely largely on observational studies or on a limited number of randomized controlled trials, many of which were conducted in highly specific patient populations. Before nicotinamide can be incorporated into international skin cancer prevention guidelines, they call for large, multicenter, randomized, placebo-controlled clinical trials to reliably evaluate its efficacy and benefit-risk profile.
In the meantime, the authors stress that proven preventive measures remain unchanged: limiting sun exposure, using broad-spectrum sunscreen regularly, wearing protective clothing, and ensuring regular dermatological surveillance for high-risk individuals. Nicotinamide remains a promising preventive strategy, but according to the authors, the scientific verdict has not yet been definitively reached.
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions.
Nicotinamide, a form of vitamin B3, has attracted growing interest in recent years as a potential strategy for preventing non-melanoma skin cancers. Inexpensive, well tolerated, and readily available, it is already recommended by some dermatologists for patients at high risk of developing new skin cancers. However, despite encouraging findings from several studies, its true clinical effectiveness remains a matter of debate.
In a critical review published in the American Journal of Clinical Dermatology, Eugene Tan and Hywel Williams reassess the latest scientific evidence on nicotinamide. The authors examine, in particular, a large retrospective study involving more than 33,000 U.S. veterans, along with the major meta-analyses published in recent years, to determine whether current evidence is sufficient to support its routine use in clinical practice.
Read next : Skin Cancer: Is Sunscreen Still Enough to Protect Us?
Encouraging Findings, but Evidence Remains Limited
The most recent retrospective study reported a 14% reduction in the overall risk of skin cancer among patients receiving nicotinamide, with a 22% reduction in the risk of cutaneous squamous cell carcinoma. The benefits appeared to be greater when treatment was initiated early, following a patient's first episode of skin cancer.
However, the authors caution that these findings should be interpreted carefully. The study has several important methodological limitations that may have overestimated the observed protective effect. These include the absence of information on major risk factors such as skin phototype, cumulative ultraviolet exposure, and photoprotection habits, as well as the potential for selection bias, difficulties in verifying long-term treatment adherence, and a study population composed almost exclusively of older men, limiting the generalizability of the results.
Researchers also place these new findings within the broader context of previous clinical trials and meta-analyses. While the ONTRAC trial, published in 2015, demonstrated a protective effect of nicotinamide in high-risk patients, other studies—particularly those involving solid organ transplant recipients—failed to show a significant benefit. Likewise, the two most recent systematic reviews concluded that the available evidence remains low in quality and does not allow a definitive conclusion that nicotinamide reduces the incidence of skin cancer.
Read next : What If Nanotechnology Redefined the Future of Sunscreens?
Should Nicotinamide Be Recommended in Clinical Practice?
This review highlights that nicotinamide has a biologically plausible mechanism of action, notably by promoting the repair of UV-induced DNA damage and improving the energy metabolism of skin cells. Nevertheless, the authors argue that biological plausibility alone is not sufficient to justify routine clinical recommendations in the absence of robust clinical evidence.
They emphasize that current data rely largely on observational studies or on a limited number of randomized controlled trials, many of which were conducted in highly specific patient populations. Before nicotinamide can be incorporated into international skin cancer prevention guidelines, they call for large, multicenter, randomized, placebo-controlled clinical trials to reliably evaluate its efficacy and benefit-risk profile.
In the meantime, the authors stress that proven preventive measures remain unchanged: limiting sun exposure, using broad-spectrum sunscreen regularly, wearing protective clothing, and ensuring regular dermatological surveillance for high-risk individuals. Nicotinamide remains a promising preventive strategy, but according to the authors, the scientific verdict has not yet been definitively reached.
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions.
Last press reviews
Does Nicotinamide Really Prevent Skin Cancer?
By Ana Espino | Published on July 01, 2026 | 4 min read<br><br><br>
Exercising in Extreme Heat: How Can Performance Be Preserved While Reducing Health Risks?
By Ana Espino | Published on June 29, 2026 | 4 min read<br><br><br>
Oropouche Virus: A New Threat to Monitor During Pregnancy?
By Ana Espino | Published on June 26, 2026 | 4 min read<br><br>